Leth A, Munch M, Nielsen B, Dollerup J
Københavns Amts Sygehus i Glostrup, lipidambulatoriet, medicinsk afdeling C.
Ugeskr Laeger. 1990 Nov 5;152(45):3354-7.
An open clinical trial comprising 59 outpatients with severe hypercholesterolemia (including 35 patients with familial hypercholesterolaemia) and considerable predisposition to ischaemic cardiac disease revealed a dosage-related pronounced effect of lovastatin on serum cholesterol and subfractions of this. After dietary regulation for a period of four months, a decrease in serum cholesterol of 11.7% was observed and after further treatment for six months with lovastatin with an average dose of 59 mg per 24 hours, the serum cholesterol decreased with a total of 45% of original value. Low density lipoprotein (LDL)-cholesterol decreased 44% and high density lipoprotein (HDL)-cholesterol increased by over 21%. Serum triglyceride fell by 20%. The serum-cholesterol/HDL-cholesterol ratio was reduced from 8.8 to 4.9. Only slight and transient subjective side-effects were observed and none of the patients dropped out of the trial for this reason. One patient with recognized ischaemic heart disease died from myocardial infarction. A tendency towards increasing liver parameters and creatin kinase was observed in the group as a whole but was not significant.
一项开放性临床试验纳入了59例重度高胆固醇血症门诊患者（其中包括35例家族性高胆固醇血症患者），这些患者有明显的缺血性心脏病易患倾向。结果显示，洛伐他汀对血清胆固醇及其亚组分有明显的剂量相关效应。经过4个月的饮食调节，血清胆固醇下降了11.7%，之后再用洛伐他汀平均剂量为每24小时59毫克进一步治疗6个月，血清胆固醇总共下降了原始值的45%。低密度脂蛋白（LDL）胆固醇下降了44%，高密度脂蛋白（HDL）胆固醇升高了21%以上。血清甘油三酯下降了20%。血清胆固醇/HDL胆固醇比值从8.8降至4.9。仅观察到轻微且短暂的主观副作用，没有患者因此退出试验。1例确诊为缺血性心脏病的患者死于心肌梗死。总体上观察到该组患者的肝脏参数和肌酸激酶有升高趋势，但不显著。
